跳到正文
原文
MedTech Dive 器械媒体· Rich Croghan and Taft Kortus·· 11 天前AI 评分45

生物医药市场投资趋势分析

Find opportunity in a shifting life sciences market

AI 导读

生物医药投资正从早期向后期阶段集中,资本倾向于支持临床验证的大型交易。战略买家通过收购加强产品管线,2025年M&A价值达2183亿美元,2026年上半年又录得1566亿美元。全球创新格局变化中,中国通过许可而非并购增加影响力。

正文

2026 US Investment outcomes monitor

Baker Tilly’s Investment Monitor: Life Sciences examines the data and market forces behind these shifts and what they could mean for investors, executives and other industry stakeholders. 

After several years of market recalibration, life sciences investment is gaining momentum. But the recovery looks different from the last cycle. 

Capital is concentrating around fewer, larger transactions. Venture investors are increasingly favoring later-stage, clinically validated companies. Strategic buyers are pursuing acquisitions to strengthen pipelines ahead of looming patent cliffs. And new dynamics—from AI-enabled drug discovery to cross-border licensing and the reshoring of R&D and manufacturing—are influencing where opportunities emerge. 

Key trends

Venture capital: Fewer, bigger, later-stage deals

Life sciences VC is increasingly concentrated in larger, later-stage investments as investors favor scaled, clinically validated companies. AI-integrated life sciences companies are also attracting significant capital as the technology moves from early hype toward execution. 

Private equity: Steady activity shaped by megadeals

PE activity remains relatively steady, while large transactions continue to have an outsized impact on overall deal value. Opportunities are also emerging in areas such as drug delivery, driven by GLP-1 demand and continued growth in capsule manufacturing. 

M&A: Strategic buyers are fortifying their pipelines

Life sciences M&A has rebounded sharply, driven largely by strategic buyers seeking scale and clinically validated assets ahead of looming patent expirations. M&A value reached a record $218.3 billion in 2025, with another $156.6 billion recorded in the first half of 2026. 

Cross-border dealmaking: Global sources of innovation are shifting

European buyers are playing a growing role in acquisitions of U.S. life sciences companies, while China’s influence is increasingly being expressed through licensing rather than inbound M&A. Chinese-originated assets are becoming an important source of innovation for U.S. and European pharmaceutical companies. 

Capital and liquidity: New pathways are gaining importance

As investors become more selective, licensing agreements, partnerships, structured investments, reverse mergers and other capital-efficient approaches are becoming more important. The life sciences IPO market is also showing signs of improvement, although access remains concentrated among companies with differentiated science, later-stage assets and clear paths to value creation. 

A market increasingly focused on scale and validation

The opportunity set is evolving. Investors are applying greater scrutiny to early-stage companies while directing capital toward differentiated science, stronger balance sheets and clearer paths to value creation. At the same time, pharmaceutical companies continue to look externally for innovation as they prepare for major patent expirations. 

Understanding these dynamics can help companies and investors make more informed decisions about capital, partnerships, acquisitions and growth.

来源:MedTech Dive 器械媒体 · medtechdive.com